No Data
No Data
Fosun Pharmaceutical (600196.SH): Cycloserine capsules approved for drug registration
Gelonghui, April 24 | Fosun Pharmaceutical (600196.SH) announced that the marketing registration application for cycloserine capsules (referred to as “the new drug”) independently developed by Shenyang Hongqi Pharmaceutical Co., Ltd., a holding subsidiary of the company, for the treatment of active tuberculosis and extrapulmonary tuberculosis (including renal tuberculosis) caused by tuberculosis bacteria sensitive to this drug and treated with first-line anti-tuberculosis drugs (such as streptomycin, isoniazid, rifampicin, and ethambutol) with poor treatment effects by first-line anti-tuberculosis drugs (such as streptomycin, isoniazid, rifampicin, and ethambutol), was recently approved by the State Drug Administration.
復星醫藥:二零二三年年報
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) Doing What It Can To Lift Shares
With a price-to-earnings (or "P/E") ratio of 25.5x Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) may be sending bullish signals at the moment, given that almost half of all companies i
A record high! Fosun Pharmaceutical (02196) was selected as one of the top 20 global pharmaceutical companies in terms of pipeline size
For the third year in a row, Fosun Pharmaceutical (02196) was selected as one of the top 25 pharmaceutical companies in the world, ranking 17th, up 7 places from the previous year.
Fosun Pharmaceutical (02196.HK): Investment funds participating in the establishment completed private equity fund filing
Gelonghui, April 22, 丨 Fosun Pharmaceutical (02196.HK) announced that on March 30, 2023, the company's holding subsidiary/enterprise Shanghai Fuyu Shengjian Enterprise Management Partnership (Limited Partnership) (hereinafter referred to as “Fuyu Shengjian”), Ningbo Fuying Investment Co., Ltd. (hereinafter referred to as “Ningbo Fuying”) and other 2 investors signed the “Anji Fuyu Chengxiang Venture Capital Partnership (Limited Partnership) Limited Partnership” with other investors to jointly fund the establishment of Anji Fucheng Yuxiang Venture Capital Partnership (Limited Partnership) “Equipment Fund”); same day, Company holding subsidiaries/corporate recovery
China Approves Fosun Unit's Phase 2 Clinical Trial for Cancer Combination Therapy
China's drug regulator granted clinical trial approval to a Shanghai Fosun Pharmaceutical (Group) (HKG:2196, SHA:600196) subsidiary for its HLX53 combination with slulimumab and bevacizumab injections
No Data